- Email: [email protected]
Premature Mortality in Pancreatic Cancer: Analysis of Lost Life-Years and Quality-Adjusted Life-Years (Qalys) in Europe
Annals of Oncology 25 (Supplement 4): iv210–iv253, 2014 doi:10.1093/annonc/mdu334.90
gastrointestinal tumours, non-colorectal 705P
abstracts
A. Carrato1, A. Falcone2, M.P. Ducreux3, J.W. Valle4, A. Parnaby5, K. Djazouli6, K. Alnwick-Allu7, A. Hutchings8 1 Medical Oncology, Hospital Ramon y Cajal, Madrid, SPAIN 2 Dept. of Oncology-presidio Ospedaliero, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, Pisa, ITALY 3 Department of Gastroenterlogy, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FRANCE 4 Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK 5 Market Access & Pricing, Celgene Corp, Boudry, SWITZERLAND 6 Oncology, Celgene Corp, Paris, FRANCE 7 Consulting, Dolon Ltd., London, UK 8 Dolon Ltd., London, UK Aim: Pancreatic Cancer (PanC) is associated with a very poor prognosis and a high patient burden. The objective of this analysis was to quantify the aggregate number of life years (LYs) and QALYs lost due to PanC in Europe each year. Methods: Estimates of incidence, life expectancy and quality of life were derived from a systematic review of PanC disease burden in Europe. Equivalent data for age-matched European population norms were obtained from the literature. Estimates of LYs lost were calculated by comparing predicted life-expectancy for PanC patients with age-matched population norms. QALYs lost were estimated by incorporating health-utility estimates for both cohorts. Aggregate LYs and QALYs lost were predicted by accounting for annual PanC incidence across EU-28 countries. We performed the analyses for both the general PanC population and metastatic (mets.) patients. Results: The average age of PanC patients at diagnosis is 71 years. Life expectancy at diagnosis is 0.3 years (4.6 months), compared to 15.1 years for an age-matched population norm – a loss of 14.7 years per person. The annual number of incident
Table: 705P Life-years and QALYs lost annually in Europe
Globocan Age-adjusted incidence, European Standard Crude Incidence, Europe
Incident Cases Aggregate per year Life-years Lost
Aggregate QALYs Lost
Annual Incidence Rate
All PanC
All PanC
10.43
79,331 44,901 1,167,488 663,792 914,594 519,606 52,872 29,925 778,095 442,397 609,549 346,301
9.95
Mets.
50,450 28,555
All PanC Mets.
Mets
742,456 422,134 581,630 330,440
Conclusions: Up to 1 million life-years are lost to PanC in Europe yearly, demonstrating the magnitude of the disease’s impact. Measurements of the life years and QALYs lost may provide a method to compare the relative burden of cancers. Similar methodology for comparing the relative burden of diseases is currently under consultation with NICE in the UK in the context of Value Based Pricing. Disclosure: A. Parnaby and K. Djazouli: I am an employee of Celgene Corporation and I declare ownership of company stocks. All other authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv239/2241513 by guest on 25 October 2019
PREMATURE MORTALITY IN PANCREATIC CANCER: ANALYSIS OF LOST LIFE-YEARS AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN EUROPE
PanC patients in Europe varied between 50,450 and 79,331depending upon the source and methodology of incidence data. The total number of LYs lost to PanC annually in Europe was as high as 1.2 million life years. Nearly half of these are due to metastatic disease. The utility of PanC patients is 0.65 compared to a population norm utility of 0.78. On average 11.5 QALYs are lost per person with PanC. Extrapolated across Europe, up to 800,000 QALYs are lost annually to PanC.
gastrointestinal tumours, non-colorectal 705P
abstracts
A. Carrato1, A. Falcone2, M.P. Ducreux3, J.W. Valle4, A. Parnaby5, K. Djazouli6, K. Alnwick-Allu7, A. Hutchings8 1 Medical Oncology, Hospital Ramon y Cajal, Madrid, SPAIN 2 Dept. of Oncology-presidio Ospedaliero, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, Pisa, ITALY 3 Department of Gastroenterlogy, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FRANCE 4 Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK 5 Market Access & Pricing, Celgene Corp, Boudry, SWITZERLAND 6 Oncology, Celgene Corp, Paris, FRANCE 7 Consulting, Dolon Ltd., London, UK 8 Dolon Ltd., London, UK Aim: Pancreatic Cancer (PanC) is associated with a very poor prognosis and a high patient burden. The objective of this analysis was to quantify the aggregate number of life years (LYs) and QALYs lost due to PanC in Europe each year. Methods: Estimates of incidence, life expectancy and quality of life were derived from a systematic review of PanC disease burden in Europe. Equivalent data for age-matched European population norms were obtained from the literature. Estimates of LYs lost were calculated by comparing predicted life-expectancy for PanC patients with age-matched population norms. QALYs lost were estimated by incorporating health-utility estimates for both cohorts. Aggregate LYs and QALYs lost were predicted by accounting for annual PanC incidence across EU-28 countries. We performed the analyses for both the general PanC population and metastatic (mets.) patients. Results: The average age of PanC patients at diagnosis is 71 years. Life expectancy at diagnosis is 0.3 years (4.6 months), compared to 15.1 years for an age-matched population norm – a loss of 14.7 years per person. The annual number of incident
Table: 705P Life-years and QALYs lost annually in Europe
Globocan Age-adjusted incidence, European Standard Crude Incidence, Europe
Incident Cases Aggregate per year Life-years Lost
Aggregate QALYs Lost
Annual Incidence Rate
All PanC
All PanC
10.43
79,331 44,901 1,167,488 663,792 914,594 519,606 52,872 29,925 778,095 442,397 609,549 346,301
9.95
Mets.
50,450 28,555
All PanC Mets.
Mets
742,456 422,134 581,630 330,440
Conclusions: Up to 1 million life-years are lost to PanC in Europe yearly, demonstrating the magnitude of the disease’s impact. Measurements of the life years and QALYs lost may provide a method to compare the relative burden of cancers. Similar methodology for comparing the relative burden of diseases is currently under consultation with NICE in the UK in the context of Value Based Pricing. Disclosure: A. Parnaby and K. Djazouli: I am an employee of Celgene Corporation and I declare ownership of company stocks. All other authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv239/2241513 by guest on 25 October 2019
PREMATURE MORTALITY IN PANCREATIC CANCER: ANALYSIS OF LOST LIFE-YEARS AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN EUROPE
PanC patients in Europe varied between 50,450 and 79,331depending upon the source and methodology of incidence data. The total number of LYs lost to PanC annually in Europe was as high as 1.2 million life years. Nearly half of these are due to metastatic disease. The utility of PanC patients is 0.65 compared to a population norm utility of 0.78. On average 11.5 QALYs are lost per person with PanC. Extrapolated across Europe, up to 800,000 QALYs are lost annually to PanC.